ArticleInternational journal of medical sciences2025
Investigation of The Hepatoprotective Potential of Liposomal Resveratrol as Polyphenols Against Liver Damage in Streptozotocin Diabetic Rat Model.
Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of tannin-rich plant fractions in hepatoprotection: a nanotechnology perspective.Discover nano · 2026Review
- Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes Mellitus is a prominent contributor to degenerative diseases globally and is often associated with hepatic injury. The dysfunction of the liver is characterized by cirrhosis, inflammation, apoptosis, and impaired antioxidant defense mechanisms. Our goal was to estimate the hepato-protecting properties of Liposomal resveratrol (LR) administered at 20 and 40 mg/kg in diabetic rat models and compare them with those of resveratrol at 40 mg/kg. The diabetes was induced in them using streptozotocin (STZ) (65 mg/kg) during a five-week long dosage. This study investigates the effects of LR and resveratrol on glucose levels, body weight, inflammatory markers (TNF-α, IL-6, NF-κB), oxidative stress parameters (MDA, catalase, GPx), apoptotic markers (caspase-3, BAX, BCL-2), liver function enzymes (SGOT, SGPT, GGT), and histopathological alterations in liver tissue. Diabetic rats infused with STZ exhibit changes in hepatic function markers, and increased inflammatory and apoptotic responses, all of which were reversed by administering LR. This reversal occurred through the downregulation of TNF-α and IL-6, inhibition of NF-κB translocation, upregulation of BCL-2, and downregulation of caspase 3 and Bax protein levels. STZ-induced diabetic rats experience a significant disruption in their antioxidant defense system, whereas LR administration notably inhibits lipid peroxidation and significantly enhances the activity of antioxidant enzymes. The histopathological analysis of liver tissue in STZ rats showed morphological changes when compared to the normal rats. This was indicative of the development of acute inflammations. In contrast, LR treatment resulted in normal liver histology with minimal presence of chronic inflammatory cells, predominantly lymphocytes. Remarkably, resveratrol alone was less effective than LR in restoring these parameters in diabetic subjects. Administration of LR effectively mitigates oxidative stress and hepatic impairment caused due to diabetes, suggesting its potential as a therapeutic agent to reduce liver dysfunction in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.